Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
42.12%
EBIT Growth (5y)
-9.73%
EBIT to Interest (avg)
-4.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.00
Sales to Capital Employed (avg)
6.67
Tax Ratio
1.78%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
0.28
EV to EBITDA
0.28
EV to Capital Employed
1.48
EV to Sales
-0.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
524.73%
ROE (Latest)
-603.65%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
OPERATING CASH FLOW(Y)
Highest at SEK -3.3 MM
NET PROFIT(HY)
Higher at SEK -2.01 MM
-26What is not working for the Company
INTEREST(9M)
At SEK 0.58 MM has Grown at inf%
NET SALES(HY)
At SEK 2.94 MM has Grown at -86.26%
NET PROFIT(HY)
At SEK -2.01 MM has Grown at -2,359.15%
ROCE(HY)
Lowest at -846.76%
RAW MATERIAL COST(Y)
Grown by 213,467.36% (YoY
DEBT-EQUITY RATIO
(HY)
Highest at 257.93 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 0 times
PRE-TAX PROFIT(Q)
At SEK -1.66 MM has Fallen at -21.18%
Here's what is working for ODI Pharma AB
Operating Cash Flow
Highest at SEK -3.3 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (SEK MM)
Net Profit
Higher at SEK -2.01 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (SEK MM)
Here's what is not working for ODI Pharma AB
Net Sales
At SEK 2.94 MM has Grown at -86.26%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (SEK MM)
Net Profit
At SEK -2.01 MM has Grown at -2,359.15%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (SEK MM)
Interest
At SEK 0.58 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (SEK MM)
Pre-Tax Profit
At SEK -1.66 MM has Fallen at -21.18%
over average net sales of the previous four periods of SEK -1.37 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (SEK MM)
Debt-Equity Ratio
Highest at 257.93 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Raw Material Cost
Grown by 213,467.36% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
